ZX008
Drug
Zogenix Inc.
Total Payments
$134,913
Transactions
47
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $134,913 | 47 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $134,913 | 47 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome | Zogenix Inc. | $134,913 | 0 |
Top Doctors Receiving Payments for ZX008
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Orlando, FL | $134,913 | 47 |
Ad
Manufacturing Companies
- Zogenix Inc. $134,913
Product Information
- Type Drug
- Total Payments $134,913
- Total Doctors 0
- Transactions 47
About ZX008
ZX008 is a drug associated with $134,913 in payments to 0 healthcare providers, recorded across 47 transactions in the CMS Open Payments database. The primary manufacturer is Zogenix Inc..
Payment data is available from 2020 to 2020. In 2020, $134,913 was paid across 47 transactions to 0 doctors.
The most common payment nature for ZX008 is "Unspecified" ($134,913, 100.0% of total).
ZX008 is associated with 1 research study, including "A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome" ($134,913).